SCHEMBL20074425

SCHEMBL20074425

NS(=O)(=O)c1ccc(Nc2cc(Cl)ccn2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.60
CDK1 P06493 1/20 0.60
CCNB1 P14635 1/20 0.60
CCNA2 P20248 1/20 0.60
CCNE1 P24864 1/20 0.60
CDK5 Q00535 1/20 0.60
CDK5R1 Q15078 1/20 0.60
CA1 P00915 11/20 0.58
CA2 P00918 11/20 0.58
CA12 O43570 5/20 0.58
CA9 Q16790 5/20 0.58
CA14 Q9ULX7 2/20 0.58
CA7 P43166 2/20 0.58
CA6 P23280 1/20 0.58
CA5A P35218 1/20 0.58
ROCK1 Q13464 1/20 0.58
CA5B Q9Y2D0 1/20 0.58
IKBKB O14920 1/20 0.53
SOS1 Q07889 2/20 0.52
TGFBR1 P36897 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12487304 0.82 CDK2 (0.60) CDK2CDK1CCNB1CCNA2CCNE1
SCHEMBL20074426 0.78 CDK1 (0.56) CDK2CDK1CCNB1CCNA2CCNE1
SCHEMBL12279274 0.76 CA1 (0.59) CDK2CDK1CCNB1CCNA2CCNE1
SCHEMBL31031226 0.76 SCN9A (0.48) CDK2CCNA2ROCK1EGFRERBB3
SCHEMBL31240706 0.75 SCN9A (0.46) ROCK1TGFBR1
SCHEMBL3871509 0.75 JAK2 (0.52) CDK2CDK1ROCK1IKBKBAURKA
SCHEMBL1395316 0.75 CDK2 (1.00) CDK2CDK1CCNB1CCNA2CCNE1
SCHEMBL11252654 0.75 CDK2 (0.60) CDK2CDK1CCNB1CCNA2CCNE1
SCHEMBL27497103 0.75 CA1 (0.75) CDK2CA1CA2CA12CA9
SCHEMBL3791868 0.74 CA2 (1.00) CDK2CDK1CCNB1CCNA2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108779115-B Five-membered heteroaromatic ring bridged ring derivative, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2021-02-26 CN disclosed
US-10906905-B2 Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2021-02-02 US disclosed
US-20200055852-A1 FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2020-02-20 US disclosed
EP-3527570-A1 FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2019-08-21 EP disclosed
WO-2018068759-A1 FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906905-B2 Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof TGFBR1, TGFB2, TGFB1 CDK2 1060/4885CDK1 1293/4885CCNB1 1486/4885
US-20200055852-A1 FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF TGFBR1, TGFB2, TGFB1 CDK2 1060/4885CDK1 1293/4885CCNB1 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.